ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Initial real-world experience with lecanemab prescribing patterns in Japan: The Longevity Improvement & Fair Evidence (LIFE) Study.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- National Monthly Outpatient Claim-Recorded Lecanemab Drug Amount in Japan During Fiscal Year 2024.Geriatrics & gerontology international · 2026Article
- Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lecanemab, an anti-amyloid-beta antibody, is approved in over 40 countries. Patient demographic data exist for the US but are limited elsewhere. This study examined early real-world lecanemab use in Japan. Methods: Using claims data from 18 municipalities, we identified patients prescribed lecanemab between December 2023 and September 2024. The study outcome was the discontinuation rate, with discontinuation defined as a ≥42-day prescription gap. Covariates included age, sex, long-term care certification, municipality size, comorbidities, Mini-Mental State Examination (MMSE) score, and Clinical Dementia Rating (CDR). Results: We identified 123 lecanemab recipients (median age: 76 years, interquartile range: 73-79 years; women: 73.2%). Most had mild impairment: 60.9% with MMSE ≥24 and 79.3% with CDR 0.5. The discontinuation rate was 1.04/100 person-months, with most occurring within 1.5 months. Discussion: In this first Asian report, lecanemab was mainly prescribed to older women with milder cognitive impairment. Early discontinuation may reflect cautious adoption in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.